biotin malii Search Results


96
Vector Laboratories biotinylated maackia amurensis lectin ii malii
Biotinylated Maackia Amurensis Lectin Ii Malii, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated maackia amurensis lectin ii malii/product/Vector Laboratories
Average 96 stars, based on 1 article reviews
biotinylated maackia amurensis lectin ii malii - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

90
Nivalis Therapeutics galanthus nivalis agglutinin-fitc
Galanthus Nivalis Agglutinin Fitc, supplied by Nivalis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galanthus nivalis agglutinin-fitc/product/Nivalis Therapeutics
Average 90 stars, based on 1 article reviews
galanthus nivalis agglutinin-fitc - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

95
Vector Laboratories 1235 biotinylated lectin malii vector laboratories
1235 Biotinylated Lectin Malii Vector Laboratories, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1235 biotinylated lectin malii vector laboratories/product/Vector Laboratories
Average 95 stars, based on 1 article reviews
1235 biotinylated lectin malii vector laboratories - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

95
Vector Laboratories biotinylated lectins maackia amurensis lectin i
Biotinylated Lectins Maackia Amurensis Lectin I, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated lectins maackia amurensis lectin i/product/Vector Laboratories
Average 95 stars, based on 1 article reviews
biotinylated lectins maackia amurensis lectin i - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

90
GeneTex malii
(A) MFI of SNA or (B) <t>MALII</t> gated on PB-derived Lin - HLADR low CD33 + CD11b + cells from lung cancer patient and healthy controls. MFI is shown as change to FMO and was determined by flow cytometry. N=8-13 donors with at least N=2 experiments. (C) MALDI-TOF mass spectra (m/z 1200–5000) of N-glycans isolated from CD33 + cells of healthy donor and lung cancer patient derived from fresh blood. The N-glycans were released by PNGaseF and permethylated prior to MALDI-TOF-TOF profiling. Main structures are depicted above the corresponding peaks. Assignments are based on composition and knowledge of biosynthetic pathways. All molecular ions are [M + Na] + . Residues above a bracket have not had their location unequivocally defined. (D) Relative quantification of N-Glycans detected in cancer patient and healthy donor derived CD33 + cells from (C) . N=1 . (E) Fresh blood from B16F10 tumor bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for SNA gated on (E) CD45 + CD11b + Ly6C + or (F) CD45 + CD11b + Ly6G + cells. MFI is shown as change to FMO. 7-8 mice per group with N=2 experiments . Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
Malii, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/malii/product/GeneTex
Average 90 stars, based on 1 article reviews
malii - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

94
Vector Laboratories biotin maackia amurensis lectin ii malii
(A) MFI of SNA or (B) <t>MALII</t> gated on PB-derived Lin - HLADR low CD33 + CD11b + cells from lung cancer patient and healthy controls. MFI is shown as change to FMO and was determined by flow cytometry. N=8-13 donors with at least N=2 experiments. (C) MALDI-TOF mass spectra (m/z 1200–5000) of N-glycans isolated from CD33 + cells of healthy donor and lung cancer patient derived from fresh blood. The N-glycans were released by PNGaseF and permethylated prior to MALDI-TOF-TOF profiling. Main structures are depicted above the corresponding peaks. Assignments are based on composition and knowledge of biosynthetic pathways. All molecular ions are [M + Na] + . Residues above a bracket have not had their location unequivocally defined. (D) Relative quantification of N-Glycans detected in cancer patient and healthy donor derived CD33 + cells from (C) . N=1 . (E) Fresh blood from B16F10 tumor bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for SNA gated on (E) CD45 + CD11b + Ly6C + or (F) CD45 + CD11b + Ly6G + cells. MFI is shown as change to FMO. 7-8 mice per group with N=2 experiments . Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
Biotin Maackia Amurensis Lectin Ii Malii, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotin maackia amurensis lectin ii malii/product/Vector Laboratories
Average 94 stars, based on 1 article reviews
biotin maackia amurensis lectin ii malii - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

99
Vector Laboratories biotinylated malii
(A) MFI of SNA or (B) <t>MALII</t> gated on PB-derived Lin - HLADR low CD33 + CD11b + cells from lung cancer patient and healthy controls. MFI is shown as change to FMO and was determined by flow cytometry. N=8-13 donors with at least N=2 experiments. (C) MALDI-TOF mass spectra (m/z 1200–5000) of N-glycans isolated from CD33 + cells of healthy donor and lung cancer patient derived from fresh blood. The N-glycans were released by PNGaseF and permethylated prior to MALDI-TOF-TOF profiling. Main structures are depicted above the corresponding peaks. Assignments are based on composition and knowledge of biosynthetic pathways. All molecular ions are [M + Na] + . Residues above a bracket have not had their location unequivocally defined. (D) Relative quantification of N-Glycans detected in cancer patient and healthy donor derived CD33 + cells from (C) . N=1 . (E) Fresh blood from B16F10 tumor bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for SNA gated on (E) CD45 + CD11b + Ly6C + or (F) CD45 + CD11b + Ly6G + cells. MFI is shown as change to FMO. 7-8 mice per group with N=2 experiments . Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
Biotinylated Malii, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated malii/product/Vector Laboratories
Average 99 stars, based on 1 article reviews
biotinylated malii - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

N/A
Introduction to ChromaLINK Labeling Technology ChromaLINK Biotin Maleimide incorporates UV traceable biotin onto thiol containing proteins peptides and or antibodies ChromaLINK Biotin Maleimide has been engineered to include many novel features As illustrated in Figure
  Buy from Supplier

N/A
The ChromaLink One Shot Antibody Biotinylation Kit provides convenient consistent and measurable biotinylation of 100 µg of antibody Each kit contains ChromaLink Biotin which incorporates a novel UV traceable chromophore in the linker arm to
  Buy from Supplier

N/A
The NHLRC1 Antibody S85 18 Biotin from Novus Biologicals is a mouse monoclonal antibody to NHLRC1 This antibody reacts with human The NHLRC1 Antibody S85 18 Biotin has been validated for the following applications Western
  Buy from Supplier

N/A
Introduction to ChromaLINK Labeling Technology ChromaLINK Biotin incorporates UV traceable biotin onto proteins containing lysine residues amine groups via a water soluble succinimidyl activated ester ChromaLINK Biotin has been engineered to include many novel features
  Buy from Supplier


Image Search Results


(A) MFI of SNA or (B) MALII gated on PB-derived Lin - HLADR low CD33 + CD11b + cells from lung cancer patient and healthy controls. MFI is shown as change to FMO and was determined by flow cytometry. N=8-13 donors with at least N=2 experiments. (C) MALDI-TOF mass spectra (m/z 1200–5000) of N-glycans isolated from CD33 + cells of healthy donor and lung cancer patient derived from fresh blood. The N-glycans were released by PNGaseF and permethylated prior to MALDI-TOF-TOF profiling. Main structures are depicted above the corresponding peaks. Assignments are based on composition and knowledge of biosynthetic pathways. All molecular ions are [M + Na] + . Residues above a bracket have not had their location unequivocally defined. (D) Relative quantification of N-Glycans detected in cancer patient and healthy donor derived CD33 + cells from (C) . N=1 . (E) Fresh blood from B16F10 tumor bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for SNA gated on (E) CD45 + CD11b + Ly6C + or (F) CD45 + CD11b + Ly6G + cells. MFI is shown as change to FMO. 7-8 mice per group with N=2 experiments . Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Journal: bioRxiv

Article Title: Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

doi: 10.1101/2023.06.29.547025

Figure Lengend Snippet: (A) MFI of SNA or (B) MALII gated on PB-derived Lin - HLADR low CD33 + CD11b + cells from lung cancer patient and healthy controls. MFI is shown as change to FMO and was determined by flow cytometry. N=8-13 donors with at least N=2 experiments. (C) MALDI-TOF mass spectra (m/z 1200–5000) of N-glycans isolated from CD33 + cells of healthy donor and lung cancer patient derived from fresh blood. The N-glycans were released by PNGaseF and permethylated prior to MALDI-TOF-TOF profiling. Main structures are depicted above the corresponding peaks. Assignments are based on composition and knowledge of biosynthetic pathways. All molecular ions are [M + Na] + . Residues above a bracket have not had their location unequivocally defined. (D) Relative quantification of N-Glycans detected in cancer patient and healthy donor derived CD33 + cells from (C) . N=1 . (E) Fresh blood from B16F10 tumor bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for SNA gated on (E) CD45 + CD11b + Ly6C + or (F) CD45 + CD11b + Ly6G + cells. MFI is shown as change to FMO. 7-8 mice per group with N=2 experiments . Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Article Snippet: Fluorophore-coupled lectins - PNA-PE (GeneTex) and SNA-FITC (GeneTex) - and biotinylated lectins – MALII (GeneTex) were used at a final concentration of 10 μg/mL.

Techniques: Derivative Assay, Flow Cytometry, Isolation, Quantitative Proteomics, Two Tailed Test

(A) PNA gated on PB-derived CD45 + Lin - HLADR low CD33 + CD11b + cells from primary lung cancer patient and healthy controls. MFI is shown as a change to FMO and was determined by flow. N=8-12 donors with at least N=2 . (B) Fresh blood from B16F10 tumor-bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for MALII or (C) PNA gated on CD45 + CD11b + Ly6C + or CD45 + CD11b + Ly6G + cells. MFI is shown as a change to FMO. 5-8 mice per group. Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test or multiple unpaired t-tests (B, C) was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Journal: bioRxiv

Article Title: Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

doi: 10.1101/2023.06.29.547025

Figure Lengend Snippet: (A) PNA gated on PB-derived CD45 + Lin - HLADR low CD33 + CD11b + cells from primary lung cancer patient and healthy controls. MFI is shown as a change to FMO and was determined by flow. N=8-12 donors with at least N=2 . (B) Fresh blood from B16F10 tumor-bearing mice and naïve wildtype mice was collected at day 14 after tumor inoculation and analyzed for MALII or (C) PNA gated on CD45 + CD11b + Ly6C + or CD45 + CD11b + Ly6G + cells. MFI is shown as a change to FMO. 5-8 mice per group. Data are presented as mean. Error bar values represent SD. Two-tailed unpaired Student’s t test or multiple unpaired t-tests (B, C) was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Article Snippet: Fluorophore-coupled lectins - PNA-PE (GeneTex) and SNA-FITC (GeneTex) - and biotinylated lectins – MALII (GeneTex) were used at a final concentration of 10 μg/mL.

Techniques: Derivative Assay, Two Tailed Test

(A) Experimental setup: SigE ΔLysM and SigE WT littermates were subcutaneously injected with B16F10 or B16F10 cells expressing sialidase (B16F10-sia). Tumor growth and probability of survival were addressed as the main read-out. (B) B16F10 and B16F10-sia cells were stained for SNA, MALII and Sialidase expression to validate the successful generation of stable cell lines. Cell lines were stained before each experiment, representative results are shown. (C) Tumor volume and (D) Kaplan-Meier survival curves from pooled data from 2 independent experiments. N=8-12 mice per group from 2 experiments. Data are presented as mean with error bars presenting SEM. Tumor growth was compared by mixed-effects analysis followed by Bonferroni’s multiple comparisons test. For survival analysis, log-rank test was used followed by Šidák correction for multiple comparisons. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Journal: bioRxiv

Article Title: Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

doi: 10.1101/2023.06.29.547025

Figure Lengend Snippet: (A) Experimental setup: SigE ΔLysM and SigE WT littermates were subcutaneously injected with B16F10 or B16F10 cells expressing sialidase (B16F10-sia). Tumor growth and probability of survival were addressed as the main read-out. (B) B16F10 and B16F10-sia cells were stained for SNA, MALII and Sialidase expression to validate the successful generation of stable cell lines. Cell lines were stained before each experiment, representative results are shown. (C) Tumor volume and (D) Kaplan-Meier survival curves from pooled data from 2 independent experiments. N=8-12 mice per group from 2 experiments. Data are presented as mean with error bars presenting SEM. Tumor growth was compared by mixed-effects analysis followed by Bonferroni’s multiple comparisons test. For survival analysis, log-rank test was used followed by Šidák correction for multiple comparisons. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Article Snippet: Fluorophore-coupled lectins - PNA-PE (GeneTex) and SNA-FITC (GeneTex) - and biotinylated lectins – MALII (GeneTex) were used at a final concentration of 10 μg/mL.

Techniques: Injection, Expressing, Staining, Stable Transfection

(A) Identification of E:T ratios to validate the suppressive capacity of CD33 + cells against CD8 + cells. Suppressive myeloid cells were generated by co-culture with A549 (pink), HeLa (green) or without cancer cells (black). Dotted lines indicate the proliferation of T cells alone with/without stimulation by IL-2, aCD3/28 microbeads. N=4 donors of N=2 experiments . (B) A549, A549 expressing sialidase (A549-sia) and A549 GNE KO cells were stained for SNA, MALII and PNA to validate the successful generation of stable cell lines. Cell lines were stained before each experiment, representative results are shown. (C) MALII staining was performed on suppressive CD33 + cells on day 7 of the experiment. N=7 donors of N=4 experiments. (D) Percentage of proliferating CD8 + cells upon co-culture (1:10 ratio) with indicated suppressive CD33 + cells. Suppressive myeloid cells were generated using HeLa or HeLa-expressing sialidase (HeLa-sia) cancer cell lines. N=3-8 donors (E) Gene ontology enrichment analysis of the top 10 up- and downregulated gene sets found in suppressive CD33 + cells generated with A549-sia compared to parental A549 cell line. (F) PNA staining was assessed on suppressive CD33 + cells after pretreatment with sialidase on day 7 of the experiment. N=9 donors of N=5 experiments. (G) Proliferating CD8 + cells in percentage co-cultured with suppressive CD33 + cells generated by A549 co-culture in a ratio of 1:5. CD33 + cells were used immediately or were pretreated with indicated sialidases. N=3 donors of N=2 experiments. (H) Percentage of proliferating CD8 + cells upon co-culture (1:10 ratio) with suppressive CD33 + cells generated by HeLa co-culture. CD33 + cells were used immediately or were pretreated with sialidase. Data are presented as mean and error bar values represent SD. Paired t-test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Journal: bioRxiv

Article Title: Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

doi: 10.1101/2023.06.29.547025

Figure Lengend Snippet: (A) Identification of E:T ratios to validate the suppressive capacity of CD33 + cells against CD8 + cells. Suppressive myeloid cells were generated by co-culture with A549 (pink), HeLa (green) or without cancer cells (black). Dotted lines indicate the proliferation of T cells alone with/without stimulation by IL-2, aCD3/28 microbeads. N=4 donors of N=2 experiments . (B) A549, A549 expressing sialidase (A549-sia) and A549 GNE KO cells were stained for SNA, MALII and PNA to validate the successful generation of stable cell lines. Cell lines were stained before each experiment, representative results are shown. (C) MALII staining was performed on suppressive CD33 + cells on day 7 of the experiment. N=7 donors of N=4 experiments. (D) Percentage of proliferating CD8 + cells upon co-culture (1:10 ratio) with indicated suppressive CD33 + cells. Suppressive myeloid cells were generated using HeLa or HeLa-expressing sialidase (HeLa-sia) cancer cell lines. N=3-8 donors (E) Gene ontology enrichment analysis of the top 10 up- and downregulated gene sets found in suppressive CD33 + cells generated with A549-sia compared to parental A549 cell line. (F) PNA staining was assessed on suppressive CD33 + cells after pretreatment with sialidase on day 7 of the experiment. N=9 donors of N=5 experiments. (G) Proliferating CD8 + cells in percentage co-cultured with suppressive CD33 + cells generated by A549 co-culture in a ratio of 1:5. CD33 + cells were used immediately or were pretreated with indicated sialidases. N=3 donors of N=2 experiments. (H) Percentage of proliferating CD8 + cells upon co-culture (1:10 ratio) with suppressive CD33 + cells generated by HeLa co-culture. CD33 + cells were used immediately or were pretreated with sialidase. Data are presented as mean and error bar values represent SD. Paired t-test was used. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.

Article Snippet: Fluorophore-coupled lectins - PNA-PE (GeneTex) and SNA-FITC (GeneTex) - and biotinylated lectins – MALII (GeneTex) were used at a final concentration of 10 μg/mL.

Techniques: Generated, Co-Culture Assay, Expressing, Staining, Stable Transfection, Cell Culture